India, Feb. 11 -- The Government of India has issued a release:
Nafithromycin has been developed by the Wockhardt group. It is a novel macrolide specifically designed for the treatment of Community Acquired Bacterial Pneumonia (CABP). The phase III clinical study of Nafithromycin in India was supported in-part by Biotechnology Industry Research Assistance council (BIRAC), a not-for-profit, Section 8, Public Sector Enterprise of the Department of Biotechnology (DBT). Central Drugs Standard Control Organisation (CDSCO) has issued marketing authorization permission for sale and distribution of Nafithromycin Tablets 400 mg, for the treatment of adults (>=18 years) with CABP, to M/s Wockhardt Limited.
The Government is supporting research &dev...